



London, 15 October 1998
EMA/CVMP/520/98

PRESS RELEASE
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
36th MEETING

Under the chairmanship of Professor R. Kroker and C. O'Sullivan the thirty-sixth meeting of the Committee for Veterinary Medicinal Products took place in London on 13 - 15 October 1998.

Opinions

- The Committee adopted Opinions for 2 Centralised products, both falling under Part B of the Annex to Council Regulation (EEC) No. 2309/93. The first was adopted further to an oral explanation provided by the Applicant and is indicated for the treatment of enteric and respiratory disease in pigs. The second Opinion will extend an existing authorisation to dogs and is indicated for the reduction of inflammation and relief of pain associated with musculo-skeletal disorders and trauma.
- The Committee agreed Opinions for 1 new substance (modification of existing MRLs) and for 2 old substances (recommendations for Annex II and III of Council Regulation (EC) No. 2377/90).
- No recommendations for inclusion in any of the annexes to Regulation 2377/90 were possible for 4 substances, due to the inadequacy of the information submitted.
- The Committee agreed an Opinion to extend the duration of provisional MRLs for 1 substance for 2 years.

	Opinions delivered since 1.1.1995	Applications under evaluation	Applications anticipated within the next 4 months
Centralised procedures	11	11	11
MRL procedures*	39**	16	7

* Applications submitted to the EMEA after 1.1.1995

** including 2 Opinions recommending definitive MRLs for substances with previously provisional MRLs

Appointment of Rapporteurs

- The Committee appointed Rapporteurs and Co-Rapporteurs for an intended application falling under Part A of the Annex to Council Regulation (EEC) No. 2309/93 and for 2 applications (1 full, 1 extension) under the MRL procedure.

Antimicrobial Resistance

The Committee received a comprehensive report from the Chairman of its ad-hoc expert working group on Antimicrobial Resistance. A considerable amount of data have been obtained from throughout the E.U. and have been collated by the EMEA Secretariat. Preparation of the final report is underway and will encompass the patterns of antimicrobial use in veterinary medicine, resistance development and its effects in veterinary medicine, and a qualitative risk assessment of the likely transfer of such resistance to man. The Committee aims to finalise the report by the beginning of the second quarter of 1999.

Availability of Medicines

The Committee endorsed the proposals of the ad-hoc group on the Availability of Medicines to identify the specific indications in both major and minor species where products are no longer available for therapy; the support of the Veterinary Mutual Recognition Facilitation Group would also be instrumental in this initiative. Further measures are envisaged once such areas where gaps exist are identified and a preliminary report is expected during the first quarter of 1999.

Miscellaneous Items

- The next meeting of the CMVP will be held on 10 - 12 November 1998.

Peter G.H. Jones
Head, Veterinary Medicines Evaluation Unit

This press release and other documents are available on the Internet at the following address:
<http://www.eudra.org/emea.html>

Maximum Residue Limits for New Substances adopted by the Community since 1.1.1995

(Status: October 1998)

Substance a) INN	Therapeutic area a) Target species	EMEA/CVMP a) Validation b) Opinion c) Active time d) Clockstop	Commission a) Sent to Commission b) Date of the regulation c) OJ No.
a) Difloxacin	a) Chicken, turkeys	a) 16.05.95 b) 15.12.95 c) 134 days d) 49 days	a) 13.02.96 b) 08.07.96 c) OJ No. L 170 of 09.07.96
a) Ketoprofen (extension)	a) Porcine	a) 15.05.95 b) 22.03.96 c) 85 days d) 217 days	a) 25.04.96 b) 06.09.96 c) OJ No. L 226 of 07.09.96
a) Diclazuril	a) Ovine	a) 12.12.95 b) 24.04.96 c) 104 days d) 0	a) 24.05.96 b) 21.10.96 c) OJ No. L 269 of 22.10.96
a) Eprinomectin	a) Bovine	a) 22.02.96 b) 25.06.96 c) 108 days d) 0	a) 26.07.96 b) 08.01.97 c) OJ No. L 5 of 09.01.97
a) Doramectin (modification)	a) Bovine	a) 14.05.96 b) 24.07.96 c) 70 days d) 0	a) 23.08.96 b) 14.02.97 c) OJ No. L 45 of 15.02.97
a) Praziquantel	a) Ovine	a) 03.08.95 b) 18.09.96 c) 187 days d) 152 days	a) 16.10.96 b) 25.04.97 c) OJ No. L 110 of 26.04.97
a) Moxidectin (modification)	a) Bovine and Ovine	a) 12.06.96 b) 18.09.96 c) 97 days d) 0	a) 16.10.96 b) 25.04.97 c) OJ No. L 110 of 26.04.97
a) Difloxacin (modification)	a) Chicken, Turkeys	a) 10.07.96 b) 23.10.96 c) 104 days d) 0	a) 19.11.96 b) 25.04.97 c) OJ No. L 110 of 26.04.97
a) Ivermectin (extension)	a) Deer	a) 20.08.96 b) 11.12.96 c) 86 days d) 0	a) 09.01.97 b) 23.04.97 c) OJ No. L 106 of 24.04.97
a) Amitraz (extension)	a) Bees	a) 18.10.96 b) 12.02.97 c) 115 days d) 0	a) 12.03.97 b) 24.09.97 c) OJ No. L 263 of 25.09.97
a) Doramectin (extension)	a) Swine and Ovine	a) 10.06.96 b) 12.02.97 c) 118 days d) 127 days	a) 12.03.97 b) 24.09.97 c) OJ No. L 263 of 25.09.97
a) Cefazolin (extension)	a) Ovine and Caprine	a) 05.06.97 b) 10.09.97 c) 97 days d) 0	a) 10.10.97 b) 16.01.98 c) OJ No. L 11 of 17.01.98

Substance a) INN	Therapeutic area a) Target species	EMEA/CVMP a) Validation b) Opinion c) Active time d) Clockstop	Commission a) Sent to Commission b) Date of the regulation c) OJ No.
a) Isoflurane	a) Equine	a) 13.05.96 b) 07.05.97 c) 200 days d) 158 days	a) 05.06.97 b) 23.02.98 c) OJ No. L 53 of 24.02.98
a) Teflubenzuron	a) Fish	a) 20.01.97 b) 07.05.97 c) 105 days d) 0	a) 05.06.97 b) 23.02.98 c) OJ No. L 53 of 24.02.98
a) Florfenicol (extension)	a) Fish	a) 29.01.96 b) 16.07.97 c) 129 days d) 404 days	a) 12.08.97 b) 18.03.98 c) OJ No. L 82 of 19.03.98
a) Moxidectin (extension)	a) Equidae	a) 09.04.97 b) 16.07.97 c) 96 days d) 0	a) 12.08.97 b) 18.03.98 c) OJ No. L 82 of 19.03.98
a) Praziquantel (extension)	a) Equidae	a) 15.09.97 b) 14.01.98 c) 120 days d) 0	a) 09.02.98 b) 27.05.98 c) OJ No. L 154 of 28.05.98
a) Meloxicam	a) Bovine	a) 28.03.96 b) 11.06.97 c) 212 days d) 229 days	a) 09.07.97 b) 17.07.98 c) OJ No. L 205 of 22.07.98
a) Tilimicosin (extension)	a) Chicken	a) 14.07.97 b) 12.11.97 c) 111 days d) 0	a) 12.12.97 b) 09.09.98 c) OJ No. L 250 of 10.09.98

Maximum Residue Limits for Old Substances adopted by the CVMP and the Community
 (Status: October 1998)

TOTAL 425			
Annex I	Annex II	Annex III	Annex IV
52	323	39	11
Published in the Official Journal of the European Communities: 331			

**Veterinary Medicinal Products that have been granted a Community marketing authorisation
 under the centralised procedure**

(Status: October 1998)

Product a) Brandname b) INN c) Part A/B	Company a) Name b) Origin	Therapeutic area a) Target species b) Indication	Presentation a) Form b) Dosage c) No. Of presentations	EMEA/CVMP a) Validation b) Opinion c) Active time d) Clockstop	Commission a) Opinion received b) Decision c) Notification d) OJ No.
a) Nobi-vac-Porcoli b) Inactivated vaccine c) Part A	a) Intervet International b) NL	a) Piglets b) Neonatal colibacillosis	a) Solution for injection b) Multidose c) 2	a) 01.01.95 b) 27.07.95 c) 107 days d) 94 days	a) 24.08.95 b) 29.02.96 c) 04.03.96 d) OJ No. C96 of 29.03.96
a) Pentofel b) Vaccine c) Part A	a) Fort Dodge Laboratories b) IRL	a) Cats b) Rhinotracheitis	a) Solution for injection b) Monodose c) 3	a) 16.06.95 b) 18.09.96 c) 208 days d) 235 days	a) 17.10.96 b) 05.02.97 c) 06.02.97 d) OJ No. C63 of 28.02.97
a) Quadrisol b) Vedaprofen c) Part B	a) Intervet International b) NL	a) Horses b) Control of inflammation	a) Oral gel b) 100mg/ml c) 1	a) 07.05.96 b) 16.07.97 c) 209 days d) 235 days	a) 14.08.97 b) 04.12.97 c) 05.12.97 d) OJ No. C392 of 24.12.97
a) Metacam b) Meloxicam c) Part B	a)Boehringer Ingelheim b) DE	a) Cattle b) Adjunctive therapy in acute respiratory infection	a) Solution for injection b) 5mg/ml c) 1	a) 24.06.96 b) 16.07.97 c) 208 days d) 180 days	a) 14.08.97 b) 07.01.98 c) 08.01.98 d) OJ No. C32 of 30.01.98
a) Dicural b) Difloxacin c) Part B	a) Fort Dodge Animal Health b) NL	a) Poultry b) Antibacterial for systematic use	a) Oral solution b) 100mg/ml c) 2	a) 06.12.95 b) 11.06.97 c) 218 days d) 337 days	a) 11.07.97 b) 16.01.98 c) 20.01.98 d) OJ No. C63 of 27.02.98
a) Clomicalm b) Clomipramine c) Part B	a) Ciba-Geigy b) FR	a) Dogs b) Treatment of anxieties	a) Tablets b) 5, 20 and 80mg c) 3	a) 13.11.96 b) 12.11.97 c) 210 days d) 156 days	a) 12.12.97 b) 01.04.98 c) 02.04.98 d) OJ No. C126 of 24.04.98
a) Neocolipor b) Inactivated vaccine c) Part A	a) Rhône-Mérieux b) FR	a) Piglets b) Passive immunisation against neonatal colibacillosis	a) Suspension for injection b) 2ml c) 5	a) 02.10.96 b) 10.12.97 c) 191 days d) 245 days	a) 09.01.98 b) 14.04.98 c) 15.04.98 d) OJ No. C126 of 24.04.98
a) Nobilis IB4-91 b) Live vaccine c) Part B	a) Intervet International b) NL	a) Poultry, chicken b) Live vaccine against infectious bronchitis	a) Solution b) 30ml/1000 doses c) 5	a) 16.10.96 b) 12.11.97 c) 210 days d) 184 days	a) 12.12.97 b) 09.06.98 (corrigendum 05.08.98) c) 10.06.98 d) OJ No. C200 of 26.06.98
a) Suvaxyn Aujeszky 783+ O/W b) Live vaccine c) Part A	a) Solvay Duphar b) NL	a) Pigs b) Vaccine against Aujeszky disease	a) Solution for injection b) 2ml c) 3	a) 19.10.96 b) 08.04.98 c) 208 days d) 328 days	a) 08.05.98 b) 07.08.98 c) 10.08.98 d) OJ No. C269 of 28.08.98